# Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/cisplatin-versus-carboplatin-in-combination-with-third-generation-drugs-for/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Tiago Biachi De Castria,Edina MK da Silva,Aécio Flávio Teixeira de Góis,Rachel Riera |
| Citations | 122 |
| DOI | 10.1002/14651858.cd009256.pub2 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://www.ncbi.nlm.nih.gov/pmc/articles/6956680 |
| OpenAlex ID | https://openalex.org/W2123393316 |
| PMID | 23949842 |
| Type | article |
| Year | 2013 |

## Paper authors

- [Rachel Riera](https://scholariq.org/researchers/rachel-riera/)

## Paper journal

- [Cochrane Database of Systematic Reviews](https://scholariq.org/journals/cochrane-database-of-systematic-reviews/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.